Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with
coagulopathy but the optimal prophylactic anticoagulation therapy remains uncertain and …

Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …

Background/Aim: To investigate the efficacy (prognosis, coagulation/inflammation
biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 …

Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …

Although primarily affecting the respiratory system, COVID-19 causes multiple organ
damage. One of its grave consequences is a prothrombotic state that manifests as …

Objective To evaluate whether early initiation of prophylactic anticoagulation compared with
no anticoagulation was associated with decreased risk of death among patients admitted to …

Abstract Purpose of Review We aim to provide a comprehensive analysis of
hypercoagulability in individuals affected by COVID-19. Our goal is to describe the …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Early in the COVID-19 pandemic, it became clear that coagulopathy leading to
macrovascular and microvascular thrombotic events was a considerable potential …